1 Min Read
* Soleno Therapeutics Inc says David O’Toole, company’s chief financial officer, will transition from Soleno in mid-September - SEC filing
* Says Jonathan R. Wolter appointed interim CFO Source text: (bit.ly/2x898M3) Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.